Morgan Stanley Curis Inc Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.99 $104 - $181	183 Added 0.56%	32,650 $27,000
Q1 2023 May 15, 2023	SELL	$0.51 - $0.78 $100,775 - $154,127	-197,599 Reduced 85.89%	32,467 $19,000
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $3,905 - $143,098	-8,310 Reduced 3.49%	230,066 $126,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $64,596 - $1.31 Million	87,293 Added 57.78%	238,376 $167,000
Q2 2022 Oct 27, 2022	SELL	$0.71 - $2.43 $1.51 Million - $5.16 Million	-2,125,383 Reduced 93.36%	151,083 $149,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $1.51 Million - $5.16 Million	-2,125,383 Reduced 93.36%	151,083 $149,000
Q1 2022 Oct 27, 2022	BUY	$2.31 - $5.13 $4.91 Million - $10.9 Million	2,125,383 Added 1406.77%	2,276,466 $5.42 Million
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $4.53 Million - $10.1 Million	1,960,397 Added 620.24%	2,276,466 $5.42 Million
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $272,976 - $496,264	-61,343 Reduced 16.25%	316,069 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $2.62 Million - $3.34 Million	377,412 New	377,412 $2.95 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.